Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19

Showing 19 citing articles:

RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Tonia Kirschner, Matthias Müller, Daniel Rauh
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6044-6051
Closed Access | Times Cited: 9
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6
Shuai Zhao, Jingwen Luo, Pingping Xu, et al.
International Journal of Biological Macromolecules (2025), pp. 142667-142667
Closed Access
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Charles Parry, Francesca Pellicano, Alexander W. Schüttelkopf, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
Zhiyan Jiang, Yan Li, Xin Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117627-117627
Closed Access | Times Cited: 4
Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020
Yanqing Liu, Jie Chen, Xiang Li, et al.
Pharmacological Research (2025) Vol. 212, pp. 107577-107577
Open Access
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Yongting Liu, Bin Xie, Qiong Chen
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display
Mirai Kage, Ryuji Hayashi, Atsushi Matsuo, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117830-117830
Closed Access | Times Cited: 3
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Bennett Adam Caughey, John H. Strickler
Drugs (2023) Vol. 84, Iss. 1, pp. 27-44
Closed Access | Times Cited: 8
Development of PROTACS degrading KRAS and SOS1
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
KRAS takes the road to destruction
Adrienne D. Cox, Channing J. Der
Science (2024) Vol. 385, Iss. 6715, pp. 1274-1275
Closed Access | Times Cited: 2
Genomic Landscape of Endometrial, Ovarian, and Cervical Cancers in Japan from the Database in the Center for Cancer Genomics and Advanced Therapeutics
Qian Xi, Hidenori Kage, Miho Ogawa, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 136-136
Open Access | Times Cited: 5
Targeted KRASG12Vdegradation elicits efficient and durable lung adenocarcinoma regressionin vivo
Alberto J. M. Martín, Inmaculada García-Peréz, Sonia San José, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery
Taylor E. Escher, Simseok A. Yuk, Qian Yuan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Genomic landscape of endometrial, ovarian and cervical cancers in Japan from database in the Center for Cancer Genomics and Advanced Therapeutics
Qian Xi, Hidenori Kage, Miho Ogawa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top